Elevance Health, Inc. (NYSE:ELV) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. decreased its holdings in Elevance Health, Inc. (NYSE:ELV) by 6.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 86,600 shares of the company’s stock after selling 6,400 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Elevance Health were worth $37,668,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of ELV. Milestone Asset Management LLC boosted its stake in shares of Elevance Health by 2.2% during the 1st quarter. Milestone Asset Management LLC now owns 1,122 shares of the company’s stock worth $488,000 after acquiring an additional 24 shares in the last quarter. Jacobi Capital Management LLC boosted its stake in shares of Elevance Health by 3.2% during the 4th quarter. Jacobi Capital Management LLC now owns 882 shares of the company’s stock worth $325,000 after acquiring an additional 27 shares in the last quarter. McLean Asset Management Corp boosted its stake in shares of Elevance Health by 2.3% during the 1st quarter. McLean Asset Management Corp now owns 1,439 shares of the company’s stock worth $620,000 after acquiring an additional 32 shares in the last quarter. Keystone Financial Services boosted its stake in shares of Elevance Health by 2.4% during the 4th quarter. Keystone Financial Services now owns 1,436 shares of the company’s stock worth $530,000 after acquiring an additional 33 shares in the last quarter. Finally, Accurate Wealth Management LLC boosted its stake in shares of Elevance Health by 5.1% during the 1st quarter. Accurate Wealth Management LLC now owns 674 shares of the company’s stock worth $296,000 after acquiring an additional 33 shares in the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Elevance Health Trading Down 0.4%

Shares of ELV opened at $384.49 on Friday. The company has a market capitalization of $86.87 billion, a PE ratio of 15.01, a price-to-earnings-growth ratio of 1.18 and a beta of 0.60. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.50 and a current ratio of 1.45. The stock has a fifty day moving average of $404.71 and a two-hundred day moving average of $400.17. Elevance Health, Inc. has a fifty-two week low of $357.45 and a fifty-two week high of $567.26.

Elevance Health (NYSE:ELV) last issued its earnings results on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, beating analysts’ consensus estimates of $10.60 by $1.37. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%. The firm had revenue of $48.77 billion for the quarter, compared to analysts’ expectations of $46.26 billion. As a group, analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th will be given a dividend of $1.71 per share. This represents a $6.84 dividend on an annualized basis and a yield of 1.78%. The ex-dividend date is Tuesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is presently 26.69%.

Insider Activity at Elevance Health

In related news, CFO Mark Kaye sold 4,588 shares of the company’s stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the completion of the sale, the chief financial officer now directly owns 18,977 shares of the company’s stock, valued at approximately $8,061,809.14. This represents a 19.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on ELV shares. Truist Financial set a $500.00 price target on Elevance Health and gave the stock a “buy” rating in a research note on Monday, June 9th. Robert W. Baird reaffirmed a “neutral” rating and issued a $529.00 target price (down previously from $625.00) on shares of Elevance Health in a research note on Tuesday, April 15th. Guggenheim reaffirmed a “buy” rating and issued a $518.00 target price on shares of Elevance Health in a research note on Wednesday, April 23rd. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Elevance Health in a research note on Friday, March 28th. Finally, Argus set a $465.00 target price on Elevance Health in a research note on Friday, April 25th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $498.87.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.